Xyleme CDS Portal
{{‘document.preview.not.available’ | i18n}} {{‘document.preview.open.in.new.window’ | i18n}} {{‘document.preview.click.in.new.window’ | i18n}}
{{‘document.preview.not.available’ | i18n}} {{‘document.preview.open.in.new.window’ | i18n}} {{‘document.preview.click.in.new.window’ | i18n}}
The U.S. Food and Drug Administration (FDA) has issued a safety communication noting the potential need for early device replacement of Boston Scientific Corporation Accolade…
With your help, ACC Advocacy actively works with Congress, state legislators, and other key decision makers to transform cardiovascular care and improve heart health. However,…
Congress must pass funding legislation by Dec. 20 to prevent a government shutdown. Although a continuing resolution (CR) proposed earlier this week included several important…
The U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) announced the addition of empty intravenous (IV) containers to the agency’s…
The cardiovascular community continues to argue for long-term solutions, not merely short-term patches.
Presenting and learning from real-world accountable care cardiovascular arrangements was the focus of ACC’s sixth annual Value-Based Care in Cardiology Forum, held Dec. 5 in…
The U.S. Senate passed the Cardiomyopathy Health Education, Awareness, Research, and Training in the Schools (HEARTS) Act (H.R. 6829), a major ACC Advocacy priority, on…
When a graduating cardiology fellow begins their job search, there is ample reason for excitement and optimism. They are finally finishing a minimum of 14…
Cardiology magazine, ACC’s member publication, focuses on hot topics in the field, profiles of influential and rising star members, and putting the spotlight on facilities…
The U.S. Food and Drug Administration (FDA) has approved acoramidis as a treatment to help reduce cardiovascular death and cardiovascular-related hospitalization in patients with transthyretin…